美国ICU来源碳青霉烯不敏感铜绿假单胞菌及新型β-内酰胺组合药物体外活性
研究分析了2017年7月至2018年6月美国36家医院ICU分离的538株铜绿假单胞菌,发现35%对碳青霉烯不敏感,且呼吸道标本更常见。新型β-内酰胺组合药物头孢他啶-阿维巴坦和亚胺培南-瑞来巴坦对多数碳青霉烯不敏感菌株保持体外活性。
要点
- 美国ICU铜绿假单胞菌中35%对碳青霉烯不敏感,呼吸道来源更常见。
- 头孢他啶-阿维巴坦和亚胺培南-瑞来巴坦对碳青霉烯不敏感菌株敏感性均超过75%。
- 新型β-内酰胺组合药物可能用于治疗碳青霉烯不敏感铜绿假单胞菌感染。
核心结论
- 美国ICU中碳青霉烯不敏感铜绿假单胞菌常见,尤其呼吸道来源。
- 新型β-内酰胺组合药物对碳青霉烯不敏感菌株保持良好体外活性。
研究设计与样本
- 2017年7月至2018年6月,美国36家地理分布不同的医院ICU连续收集非重复铜绿假单胞菌538株,来自血液和呼吸道标本。
- 采用CLSI参考肉汤微量稀释法测定MIC和敏感性。
主要发现
- 538株ICU铜绿假单胞菌中35%对碳青霉烯不敏感,呼吸道标本比血流标本更常见。
- 头孢他啶-阿维巴坦敏感性92.8%,MIC50为2 μg/ml,MIC90为8 μg/ml。
- 亚胺培南-瑞来巴坦敏感性91.5%,MIC50为0.25 μg/ml,MIC90为2 μg/ml。
- 头孢他啶敏感性77.1%,MIC50为4 μg/ml,MIC90为64 μg/ml。
- 美罗培南敏感性72.7%,MIC50为1 μg/ml,MIC90为16 μg/ml;亚胺培南敏感性67.1%,MIC50为2 μg/ml,MIC90为16 μg/ml。
关键数值与推荐
- 碳青霉烯不敏感定义为对亚胺培南或美罗培南不敏感,观察到的比例为35%。
- 头孢他啶-阿维巴坦敏感性92.8%,亚胺培南-瑞来巴坦敏感性91.5%。
临床怎么用
- 对于ICU来源的碳青霉烯不敏感铜绿假单胞菌感染,可考虑新型β-内酰胺组合药物。
- 呼吸道标本分离的铜绿假单胞菌需关注碳青霉烯不敏感风险。
局限性
- 研究仅纳入美国36家医院ICU的分离株,结论外推需谨慎。
- 亚胺培南-瑞来巴坦为研究性药物,体外结果需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pseudomonas aeruginosa, a frequent pathogen in the intensive care unit (ICU), has the propensity to develop antibiotic resistance. In particular, carbapenem-nonsusceptible (NS) P. aeruginosa poses tremendous challenges, and new antibiotics will be needed to treat this phenotype. Here we determine carbapenem nonsusceptibility rates for contemporary P. aeruginosa isolates from U.S. ICUs and in vitro activities of new β-lactam combination agents. Between July 2017 and June 2018, consecutive nonduplicate P. aeruginosa isolates from blood and respiratory tract sources were recovered from patients admitted to the ICUs of 36 geographically diverse U.S. hospitals. Antimicrobial susceptibility to the following antipseudomonal agents was tested: ceftazidime, imipenem, meropenem, ceftazidime-avibactam, and imipenem-relebactam (an investigational β-lactam/β-lactamase inhibitor). MICs and susceptibility rates were measured using Clinical and Laboratory Standards Institute reference broth microdilution methodology. Among the 538 consecutive ICU P. aeruginosa isolates collected, carbapenem nonsusceptibility was observed for 35% of the isolates and was more common among respiratory tract versus bloodstream specimens. Susceptibility rates, MIC50 values, and MIC90 values were as follows: ceftazidime-avibactam, 92.8%, 2 μg/ml, and 8 μg/ml; imipenem-relebactam, 91.5%, 0.25 μg/ml, and 2 μg/ml; ceftazidime, 77.1%, 4 μg/ml, and 64 μg/ml; meropenem, 72.7%, 1 μg/ml, and 16 μg/ml; imipenem, 67.1%, 2 μg/ml, and 16 μg/ml. Most (>75%) of the carbapenem-NS isolates were susceptible to ceftazidime-avibactam and imipenem-relebactam. In these U.S. hospital ICUs, carbapenem-NS P. aeruginosa isolates from respiratory sources were frequently observed. Novel β-lactam combination agents appear to retain active in vitro susceptibility profiles against these isolates and may play a role in the treatment of infections caused by carbapenem-NS P. aeruginosa strains.
引用
- Asempa TE, Nicolau DP, Kuti JL, et al. Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents. J Clin Microbiol. 2019. PMID: 31118271. doi:10.1128/JCM.00535-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。